Literature DB >> 1677571

Binding of [3H]-p-aminoclonidine to alpha 2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes.

J E Piletz1, A C Andorn, J R Unnerstall, A Halaris.   

Abstract

Characterization of the binding of [3H]p-aminoclonidine ([3H]PAC) to purified plasma membranes from human platelets has revealed multiple binding sites. [3H]PAC identified site-1 in the picomolar affinity range (site-1 KD estimates ranged from 13 to 94 pM). Site-1 displayed a rank order of competition by various compounds for [3H]PAC, indicative of an alpha 2-adrenoceptor, and was sensitive to 0.1 mM GTP. [3H]PAC also identified a second site with nanomolar affinity (site-2 KD estimates ranged from 0.7 to 1.7 nM). In the presence of 0.1 mM GTP, site-2 was not diminished significantly. Also in contrast to site-1, site-2 displayed low affinity for yohimbine (YOH), (-)-epinephrine and (-)-norepinephrine (NE). Therefore, site-2 could not be an active alpha 2-adrenoceptor; instead it had properties similar to a previously reported imidazoline-preferring binding site. A third site (site-3) bound [3H]PAC with a KD for site-3 of 26.6 +/- 10.0 nM (SD). Site-3 had a rank order of competition by various compounds for 5 nM [3H]yohimbine ([3H]YOH) binding which was indicative of an alpha 2-adrenoceptor. (-)-NE competed for 5 nM [3H]YOH binding at two sites: site-1 Ki = 32 pM, site-3 Ki = 239 nM. Treatment with 0.1 mM GTP completely removed site-1 and transferred the competitive binding of (-)-NE to low affinity (Ki = 437 nM). Thus, site-3 appears to be a free alpha 2-adrenoceptor. Bmax estimates for untreated membranes, derived from simultaneous multi-experiment curve-fitting analyses, were site-1 = 36 +/- 29 fmol/mg plasma membrane protein, site-2 = 95 +/- 34 fmol/mg and site-3 = 154 +/- 35 fmol/mg. We are the first to report a site for [3H]PAC binding on platelets (site-2) with properties uncharacteristic of an adrenoceptor. This observation appears to be due to our use of purified plasma membrane and low ionic strength buffer. These studies relate to reports of increased binding of [3H]PAC to platelets from depressed patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677571     DOI: 10.1016/0006-2952(91)90320-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Clonidine and yohimbine modulate the effects of naloxone on novelty-induced hypoalgesia.

Authors:  J Rochford; P Dawes
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  LNP 906, the first high-affinity photoaffinity ligand selective for I1 imidazoline receptors.

Authors:  Dragan Urosevic; Urosevic Dragan; Stephan Schann; Schann Stephan; Jean-Daniel Ehrhardt; Ehrhardt Jean-Daniel; Pascal Bousquet; Bousquet Pascal; Hugues Greney; Greney Hugues
Journal:  Br J Pharmacol       Date:  2004-06       Impact factor: 8.739

3.  Binding of [3H]clonidine to I1-imidazoline sites in bovine adrenal medullary membranes.

Authors:  G J Molderings; D Moura; K Fink; H Bönisch; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

4.  A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.

Authors:  P Ernsberger; M A Haxhiu; L M Graff; L A Collins; I Dreshaj; D L Grove; M E Graves; S G Schäfer; M O Christen
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

Review 5.  The autonomic nervous system at high altitude.

Authors:  Roger Hainsworth; Mark J Drinkhill; Maria Rivera-Chira
Journal:  Clin Auton Res       Date:  2007-01-30       Impact factor: 4.435

6.  Generation and characterization of novel human IRAS monoclonal antibodies.

Authors:  Bo Wang; Ying Liu; Yajun Shan; Zhenyu Yao; Xiaolan Liu; Ruibin Su; Qihong Sun; Yuwen Cong; Jin Li
Journal:  J Biomed Biotechnol       Date:  2009-08-10

7.  Comparative In Vitro Study of Various α2-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal.

Authors:  Guillaume Porta Bonete; Anne Godier; Pascale Gaussem; Tiphaine Belleville-Rolland; Alexandre Leuci; Sonia Poirault-Chassac; Christilla Bachelot-Loza; Anne-Céline Martin
Journal:  J Clin Med       Date:  2020-03-16       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.